ライフサイエンスコーパス: alirocumab

1 cute Coronary Syndrome During Treatment With Alirocumab).

2 cute Coronary Syndrome During Treatment With Alirocumab).

3 larger absolute benefit from treatment with alirocumab.

4 higher rate of injection-site reactions with alirocumab.

5 on in the rate of cardiovascular events with alirocumab.

6 ot change significantly with the addition of alirocumab.

7 her lipid parameters at weeks 12 and 24 with alirocumab.

8 oups according to LDL-C levels achieved with alirocumab.

9 predicted MACEs, a relationship abrogated by alirocumab.

10 ere no significant adverse events related to alirocumab.

11 lipoprotein(a) level and its reduction with alirocumab.

12 7; 95% CI, 0.59 to 1.01; P=0.06) deaths with alirocumab.

13 2.28 mmol/L), after 4 months' treatment with alirocumab (0.80 mmol/L), or after 4 months' treatment w

14 analysis included 4974 patients (3182 taking alirocumab, 1174 taking placebo, 618 taking ezetimibe).

15 the incidence of cataracts was similar with alirocumab (127/9462 [1.3%]) versus placebo (134/9462 [1

16 domized placebo-phase, double-blind study of alirocumab 150 mg administered subcutaneously every 2 we

17 farction were randomized to receive biweekly alirocumab 150 mg or placebo in addition to high-intensi

18 Every patient received alirocumab 150 mg subcutaneously every 14 days in additi

19 randomly assigned in a 2:1 ratio to receive alirocumab (150 mg) or placebo as a 1-ml subcutaneous in

20 randomized to receive biweekly subcutaneous alirocumab (150 mg; n = 148) or placebo (n = 152), initi

21 5 mg (a PCSK9 inhibitor); and uptitration to alirocumab, 150 mg.

22 y in both groups from baseline to 12 months (alirocumab, 176.3+/-95.2 to 184.5+/-105.4 mm3; P=0.23; p

23 eeks apart, followed by 5 doses of 150 mg of alirocumab, 2 weeks apart.

24 Alirocumab (50 mg/kg) or vehicle was administered weekly

25 Alirocumab (50 mg/kg) or vehicle was administered weekly

26 ge LDL-C <50 mg/dL (44.7%-52.6% allocated to alirocumab, 6.5% allocated to ezetimibe, and 0% allocate

27 Alirocumab 75 mg or placebo was administered subcutaneou

28 optimized statin therapy were randomized to alirocumab 75 to 150 mg or matching placebo every 2 week

29 Randomization was to alirocumab 75/150 mg every 2 weeks or control for 24 to

30 study evaluating the efficacy and safety of alirocumab (a PCSK9 [proprotein convertase subtilisin/ke

31 This study aimed to assess the effects of alirocumab, a monoclonal antibody targeting PCSK9 to low

32 Alirocumab, a monoclonal antibody that inhibits proprote

33 this study, we evaluated the PCSK9 inhibitor alirocumab, a monoclonal antibody that robustly reduces

34 Alirocumab, a monoclonal antibody to proprotein converta

35 The effect of alirocumab, a PCSK9 (proprotein convertase subtilisin/ke

36 ry syndrome and reduction of those events by alirocumab, a PCSK9 (proprotein convertase subtilisin/ke

37 Alirocumab, a PCSK9 antibody, markedly lowers LDL-C leve

38 Alirocumab, a proprotein convertase subtilisin/kexin typ

39 e placebo group and MACE risk reduction with alirocumab according to baseline lipoprotein(a) concentr

40 Alirocumab added to intensive statin therapy has the pot

41 convertase subtilisin kexin type 9 inhibitor alirocumab added to statin therapy on plaque burden and

42 holesale acquisition costs of evolocumab and alirocumab); adopted a health-system perspective, lifeti

43 cute Coronary Syndrome During Treatment With Alirocumab), alirocumab reduced the primary outcome by 1

44 cute Coronary Syndrome During Treatment With Alirocumab), alirocumab was compared with placebo, added

45 e placebo group, treatment hazard ratios for alirocumab also decreased monotonically across achieved

46 Alirocumab also mitigated ethanol-induced microglia recr

47 Alirocumab, an antibody that blocks PCSK9 (proprotein co

48 kexin type 9 (PCSK9) inhibitors (14 639 with alirocumab and 21 257 with evolocumab) and 30 582 with c

49 HT recipients were included (57 assigned to alirocumab and 57 assigned to placebo).

50 taract incidence was observed between pooled alirocumab and control groups.

51 Alirocumab and evolocumab are monoclonal antibodies that

52 Alirocumab and evolocumab are monoclonal antibodies that

53 aimed to evaluate the efficacy and safety of alirocumab and evolocumab in patients with dyslipidaemia

54 nd 392 (4.1%) patients, respectively, in the alirocumab and placebo groups (hazard ratio [HR], 0.85;

55 ors, incident cataracts were compared in the alirocumab and placebo groups according to LDL-C levels

56 At week 24, the difference between the alirocumab and placebo groups in the mean percentage cha

57 ere similar in corresponding patients of the alirocumab and placebo groups.

58 g/dL (P < 0.001) and 0.9 mg/dL (P = NS) with alirocumab and placebo, respectively.

59 nce of cardiovascular benefit for ezetimibe, alirocumab, and evolocumab positions these drugs as add-

60 [placebo or ezetimibe]; representing 4,029 [alirocumab] and 2,114 [control] double-blind patient-yea

61 arge absolute reductions in those risks with alirocumab are a potential benefit for these patients.

62 significantly from baseline to 1 year in the alirocumab arm (72.7+/-31.7 to 31.5+/-20.7 mg/dL; P<0.00

63 DYSSEY OUTCOMES trial of the PCSK9 inhibitor alirocumab, assessing its effects on cardiovascular outc

64 nd nominally less relative risk reduction by alirocumab at lower percentiles for all 3 tests.

65 group and predictive of MACE reductions with alirocumab at the cohort level.

66 PCSK9 inhibition with alirocumab attenuated alcohol-induced hepatic triglyceri

67 CSK9 treatment using the monoclonal antibody alirocumab attenuated alcohol-induced steatohepatitis in

68 bility of three commercially available mAbs (alirocumab, brodalumab, secukinumab).

69 and its characteristics after treatment with alirocumab by quantification and characterization of ath

70 -centered metrics to capture the totality of alirocumab clinical efficacy after acute coronary syndro

71 e absolute and relative reduction of MACE by alirocumab compared with placebo was greater in high ver

72 ions, and 58 fewer deaths were observed with alirocumab compared with placebo, translating to 15.6 to

73 cute Coronary Syndrome During Treatment With Alirocumab) compared the PCSK9 inhibitor alirocumab with

74 cute Coronary Syndrome During Treatment With Alirocumab) compared the proprotein convertase subtilisi

75 ction, the addition of subcutaneous biweekly alirocumab, compared with placebo, to high-intensity sta

76 ompared with a statin alone, the addition of alirocumab cost $308 000 (UI, $197 000 to $678 000) per

77 atin and ezetimibe, replacing ezetimibe with alirocumab cost $997 000 (UI, $254 000 to dominated) per

78 Alirocumab decreased LDL-C and LDL-apoB by increasing ID

79 Additionally, alirocumab decreased the expression of pro-inflammatory

80 slipidemia despite intensive statin therapy, alirocumab decreased the risk of stroke, irrespective of

81 cute Coronary Syndrome During Treatment With Alirocumab) determined whether polyvascular disease infl

82 However, the reduction in triglycerides with alirocumab did not contribute to its clinical benefit.

83 red with 648 (9.6%) in the alirocumab group; alirocumab did not increase the risk of new-onset diabet

84 Alirocumab did not reduce hospitalization for HF, overal

85 Alirocumab did not reduce hospitalizations for HF in eit

86 This study presents novel evidence that alirocumab diminishes oxidative stress and modifies neur

87 background statin (n = 4629) were pooled by alirocumab dose (75 or 150 mg every 2 weeks) and control

88 Alirocumab dose was blindly titrated to target achieved

89 levels <0.39 mmol/L achieved with statin and alirocumab, followed by statin monotherapy, was associat

90 l to assess the effect of the treatment with alirocumab for 78 weeks on the coronary atherosclerotic

91 1.7%) showed triple regression (40.8% in the alirocumab group vs 23.0% in the placebo group; P = 0.00

92 nmol/L (n=35 versus 94, respectively, in the alirocumab group) and >=125 versus <125 nmol/L (n=23 ver

93 In the alirocumab group, 730 patients had blinded placebo subst

94 In the alirocumab group, all-cause death declined with achieved

95 The alirocumab group, as compared with the placebo group, ha

96 In the alirocumab group, neither OxPL-apoB nor Lp(a) remained s

97 In the alirocumab group, OxPL-apoB was not related to MACE risk

98 Across achieved LDL-C strata of the alirocumab group, patients differed by baseline LDL-C, l

99 In the alirocumab group, the incidence of MACE after month 4 de

100 In the alirocumab group, the reduction in maxLCBI(4mm) was smal

101 C and incidence of hemorrhagic stroke in the alirocumab group.

102 t depend on achieved LDL-C levels within the alirocumab group.

103 acebo group, compared with 648 (9.6%) in the alirocumab group; alirocumab did not increase the risk o

104 tive LDL-C levels <0.39 mmol/L (15 mg/dL) on alirocumab had blinded placebo substitution for the rema

105 statins alone, those receiving a statin plus alirocumab had lower rates of a composite outcome includ

106 Alirocumab had no effects on FCRs or PRs of very low-den

107 of death and a larger mortality benefit from alirocumab (HR, 0.71; 95% CI, 0.56 to 0.90; P(interactio

108 95% CI: 0.982-0.995; P < 0.005) but not with alirocumab (HR: 0.999; 95% CI: 0.987-1.010; P = 0.82).

109 coronary syndrome on optimal statin therapy, alirocumab improves cardiovascular outcomes at costs con

110 her research is needed to understand whether alirocumab improves clinical outcomes in this population

111 (Vascular Effects of Alirocumab in Acute MI-Patients [PACMAN-AMI]; NCT0306784

112 Treatment with alirocumab in addition to high-intensity statin therapy

113 Treatment with alirocumab in addition to high-intensity statin therapy

114 onvertase subtilisin/kexin 9 inhibition with alirocumab in addition to statin therapy early after HT

115 double-blind period, patients could receive alirocumab in an 80-week open-label period.

116 There was an absolute reduction by alirocumab in high versus low PRS groups of 6.0% and 1.5

117 mechanistic studies of the Lp(a) lowering by alirocumab in humans have been published to date.

118 nary plaque burden (PB) after treatment with alirocumab in patients with familial hypercholesterolemi

119 acteristics after 78 weeks of treatment with alirocumab in patients with familial hypercholesterolemi

120 of MACEs and death and their modification by alirocumab in patients with recent ACS and dyslipidemia

121 nct lipid-lowering therapy (LLT); the use of alirocumab in pediatric patients requires evaluation.

122 kexin type 9 (PCSK9) inhibitors [evolocumab, alirocumab, inclisiran, lerodalcibep, and enlicitide dec

123 Absolute risk reduction with alirocumab increased with increasing lipoprotein(a) meas

124 e coronary syndrome (ACS) determined whether alirocumab-induced changes in lipoprotein(a) and LDL-C i

125 Alirocumab-induced reductions of lipoprotein(a) and corr

126 nd after price reductions for evolocumab and alirocumab initiated during the fourth quarter of 2018 a

127 > 4.0mmol/L with high risk were initiated on alirocumab injection every 2 weeks.

128 Lipoprotein(a) lowering by alirocumab is an independent contributor to MACE reducti

129 eductions with the PCSK9 monoclonal antibody alirocumab may be affected by background statin dose due

130 tation patients randomly assigned to receive alirocumab, mean percent reduction in LDL-C at 2 weeks w

131 ed) were 21 and 75 mg/dL, respectively; with alirocumab, median relative reductions were 23.5% and 70

132 le-blind treatment 8 to 104 weeks; n = 3,340 alirocumab, n = 1,894 control [placebo or ezetimibe]; re

133 cute Coronary Syndrome During Treatment With Alirocumab; n=18 924) was a double-blind, randomized, pl

134 cute Coronary Syndrome During Treatment With Alirocumab; NCT01663402).

135 cute Coronary Syndrome During Treatment With Alirocumab; NCT01663402).

136 get for PCSK9 inhibitors, eg, evolocumab and alirocumab), NPC1L1 (encoding the target for ezetimibe),

137 cute Coronary Syndrome During Treatment With Alirocumab [ODYSSEY OUTCOMES]: NCT01663402).

138 cute Coronary Syndrome During Treatment With Alirocumab [ODYSSEY OUTCOMES]; NCT01663402).

139 spectively, and a relative risk reduction by alirocumab of 37% in the high PRS group (hazard ratio, 0

140 ARCHITECT (Effect of Alirocumab on Atherosclerotic Plaque Volume, Architectur

141 The ARCHITECT study (Effect of Alirocumab on Atherosclerotic Plaque Volume, Architectur

142 fied analysis, we investigated the effect of alirocumab on cardiovascular events by glycaemic status

143 MAN-AMI trial (Effects of the PCSK9 Antibody Alirocumab on Coronary Atherosclerosis in Patients With

144 he PACMAN-AMI (Effects of the PCSK9 Antibody Alirocumab on Coronary Atherosclerosis in Patients with

145 We assessed the effects of alirocumab on death after index acute coronary syndrome.

146 nalysis was designed to assess the effect of alirocumab on ischemic and hemorrhagic stroke.

147 from a parent trial evaluating the impact of alirocumab on radiologic markers of cardiovascular risk

148 The effect of alirocumab on stroke was similar among 944 patients (5.0

149 ipoprotein cholesterol-lowering therapy with alirocumab or evolocumab on individual clinical efficacy

150 olled trials (RCTs) comparing treatment with alirocumab or evolocumab vs. placebo or other lipid-lowe

151 tase subtilisin-kexin type 9 inhibition with alirocumab or evolocumab was associated with lower risk

152 Alirocumab or ezetimibe added to statin therapy.

153 Among 153 patients randomized to receive alirocumab or placebo (mean [range] age, 12.9 [8-17] yea

154 Patients were randomized to alirocumab or placebo 1 to 12 months after ACS.

155 Patients were randomized to alirocumab or placebo 1 to 12 months after acute coronar

156 -intensity statin therapy were randomized to alirocumab or placebo and followed for 2.8 years (median

157 Patients were randomized 2:1 to subcutaneous alirocumab or placebo and Q2W or Q4W.

158 ents were randomly assigned (1:1) to receive alirocumab or placebo every 2 weeks; randomisation was s

159 was a double-blind, randomized comparison of alirocumab or placebo in 18 924 patients who had an ACS

160 le-blind, placebo-controlled trial comparing alirocumab or placebo in 18 924 patients with acute coro

161 randomized early after HT to receive either alirocumab or placebo in addition to rosuvastatin.

162 participants 4 months after randomization to alirocumab or placebo in the ODYSSEY OUTCOMES trial.

163 -intensity statin therapy were randomized to alirocumab or placebo subcutaneously every 2 weeks.

164 t who were randomized to the PCSK9 inhibitor alirocumab or placebo.

165 mal statin therapy were randomly assigned to alirocumab or placebo.

166 se subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab or placebo.

167 ed to lipoprotein(a) level and is reduced by alirocumab, particularly among those with high lipoprote

168 -up of 2.8 years, MACE occurred in 47 (6.4%) alirocumab patients with limited-duration, very low achi

169 cute Coronary Syndrome During Treatment With Alirocumab), patients with recent acute coronary syndrom

170 otal hospitalizations or deaths avoided with alirocumab per 1000 patient-years of assigned treatment.

171 regression despite intensive treatment with alirocumab plus high-intensity statin.

172 rrected LDL-C levels and their reductions by alirocumab predicted the risk of MACE after recent ACS.

173 In summary, alirocumab provided consistent LDL-C reductions and was

174 The findings in this study indicate that alirocumab Q2W or Q4W significantly may be useful for re

175 Two patients receiving alirocumab Q4W experienced adverse events leading to dis

176 2 patients eligible for >=3 years follow-up, alirocumab reduced death (HR, 0.78; 95% CI, 0.65 to 0.94

177 Alirocumab reduced first occurrence of the primary compo

178 Alirocumab reduced lipoprotein(a) by 5.0 mg/dl (IQR: 0 t

179 Alirocumab reduced low-density lipoprotein cholesterol a

180 Versus placebo, alirocumab reduced low-density lipoprotein cholesterol f

181 Alirocumab reduced MACE across all strata of baseline ap

182 Overall, alirocumab reduced MACE compared with placebo [hazard ra

183 Alirocumab reduced MACE in patients without a history of

184 Alirocumab reduced median placebo-adjusted OxPL-apoB by

185 Alirocumab reduced risk of PAD events (hazard ratio [HR]

186 Syndrome During Treatment With Alirocumab), alirocumab reduced the primary outcome by 1.6% over 2.8

187 Alirocumab reduced the risk of any stroke (HR, 0.72 [95%

188 The present analysis determined whether alirocumab reduced total (first and subsequent) hospital

189 Alirocumab reduced total hospitalizations (hazard ratio,

190 Alirocumab reduced total hospitalizations with correspon

191 Alirocumab reduced total nonfatal cardiovascular events

192 Alirocumab reduced ultracentrifugally isolated LDL-C by

193 Alirocumab resulted in greater reductions in percent ath

194 Alirocumab resulted in similar relative reductions in th

195 cute Coronary Syndrome During Treatment With Alirocumab) results.

196 age, 12.9 [8-17] years; 87 [56.9%] female), alirocumab showed statistically significant reductions i

197 Every patient received 150 mg of alirocumab subcutaneiously every 14 days in addition to

198 na requiring hospitalization) was lower with alirocumab than with placebo (1.7% vs. 3.3%; hazard rati

199 With alirocumab, the change from baseline to Month 4 in lipop

200 With alirocumab, the corresponding absolute risk reduction wa

201 tin, 80 mg; add-on ezetimibe therapy; add-on alirocumab therapy, 75 mg (a PCSK9 inhibitor); and uptit

202 hypothesized that for patients treated with alirocumab there would be a reduction in risk of ischemi

203 proprotein subtilisin/kexin type 9 inhibitor alirocumab to optimized statin treatment in patients wit

204 to determine the clinical benefit of adding alirocumab to statins in ACS patients with prior CABG in

205 In alirocumab-treated patients, 839 (25.1%) achieved 2 cons

206 le regression was independently predicted by alirocumab treatment (OR: 2.83; 95% CI: 1.57-5.16; P = 0

207 Alirocumab treatment also attenuated alcohol-induced PCS

208 association of very low achieved LDL-C with alirocumab treatment at month 4 and subsequent hemorrhag

209 Alirocumab treatment did not increase the risk of new-on

210 Predicted alirocumab treatment effects were also nearly identical

211 creased PCSK9 expression in the brain, while alirocumab treatment significantly upregulated neuronal

212 The increase in apo(a) FCR during alirocumab treatment suggests that increased LDL recepto

213 After a recent acute coronary syndrome, alirocumab treatment targeting an LDL cholesterol concen

214 pid-lowering therapy and was associated with alirocumab treatment, higher baseline lipid content, and

215 After all subjects received 8 weeks of alirocumab treatment, LDL-C was reduced by 73% from base

216 er absolute and relative risk reduction with alirocumab treatment, providing an independent tool for

217 ctors, who might derive greater benefit from alirocumab treatment.

218 terol (LDL-C) predicted greater benefit from alirocumab treatment.

219 cute Coronary Syndrome During Treatment With Alirocumab) trial included participants with a recent ac

220 cute Coronary Syndrome During Treatment With Alirocumab) trial, the authors evaluated the benefit of

221 cute Coronary Syndrome During Treatment With Alirocumab) trial.

222 ilisin/kexin type 9 (PCSK9, targeted by, eg, alirocumab), using LDL as the biomarker.

223 atients achieving LDL-C goals at Week 24 for alirocumab versus control (interaction P-values non-sign

224 Incidence of adverse events was similar for alirocumab versus control, except for a higher rate of i

225 r (QALY) was determined with the addition of alirocumab versus placebo and, based on clinical efficac

226 Treatment with alirocumab versus placebo, added to statin, did not infl

227 uenced by treatment with the PCSK9 inhibitor alirocumab versus placebo, and whether that incidence wa

228 <0.0001) and absolute reduction in MACE with alirocumab versus placebo.

229 e in percent atheroma volume was -2.13% with alirocumab vs -0.92% with placebo (difference, -1.21% [9

230 ore burden index within 4 mm was -79.42 with alirocumab vs -37.60 with placebo (difference, -41.24 [9

231 mal fibrous cap thickness was 62.67 mum with alirocumab vs 33.19 mum with placebo (difference, 29.65

232 s occurred in 70.7% of patients treated with alirocumab vs 72.8% of patients receiving placebo.

233 herence tomography to compare the effects of alirocumab vs placebo in patients receiving high-intensi

234 etween triglyceride levels and the effect of alirocumab vs placebo on cardiovascular outcomes using p

235 and 21.8%; the absolute risk reduction with alirocumab was 0.4% (95% CI: -0.1% to 1.0%), 1.3% (95% C

236 A 1-mg/dl reduction in lipoprotein(a) with alirocumab was associated with a HR of 0.994 (95% CI: 0.

237 Reduction in PAD events with alirocumab was associated with baseline quartile of lipo

238 Alirocumab was associated with consistent relative risk

239 poproteins despite intensive statin therapy, alirocumab was associated with large absolute reductions

240 Alirocumab was blindly titrated to 150 mg if LDL-C remai

241 Syndrome During Treatment With Alirocumab), alirocumab was compared with placebo, added to high-inte

242 The safety of alirocumab was evaluated in patients with at least 2 con

243 for major adverse cardiovascular events with alirocumab was numerically greater (but not statisticall

244 Alirocumab was titrated to target LDL cholesterol concen

245 cute Coronary Syndrome During Treatment With Alirocumab) was a double-blind, randomized comparison of

246 cute Coronary Syndrome During Treatment With Alirocumab) was developed to estimate costs and outcomes

247 Patients randomized to alirocumab were also more likely to survive to the end o

248 Patients on alirocumab were classified in prespecified strata of LDL

249 LDL-C levels <25 or <15 mg/dl on alirocumab were not associated with an increase in overa

250 ataracts, even when achieved LDL-C levels on alirocumab were very low.

251 cute Coronary Syndrome During Treatment with Alirocumab) were then combined in a meta-analysis to ass

252 Over a period of 78 weeks, alirocumab, when added to statin therapy at the maximum

253 cute Coronary Syndrome During Treatment With Alirocumab) which compared alirocumab with placebo in 18

254 ristics and adherence, patients treated with alirocumab who achieved LDL-C levels <25 mg/dL had a red

255 In patients treated with alirocumab with >= 2 LDL-C values < 15 mg/dL (0.39 mmol/

256 In patients treated with alirocumab with >= 2 LDL-C values < 25 mg/dL (0.65 mmol/

257 ents within the ODYSSEY trials that compared alirocumab with controls (placebo/ezetimibe), mainly as

258 convertase subtilisin/kexin type 9 inhibitor alirocumab with placebo in 18 924 patients with recent a

259 ng Treatment With Alirocumab) which compared alirocumab with placebo in 18 924 patients with recent a

260 DYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent a

261 ODYSSEY Outcomes compared alirocumab with placebo in 18,924 patients with recent a

262 DYSSEY OUTCOMES trial (NCT01663402) compared alirocumab with placebo in 18,924 patients with recent a

263 at 1315 sites in 57 countries, that compared alirocumab with placebo in patients who had been admitte

264 ith Alirocumab) compared the PCSK9 inhibitor alirocumab with placebo in patients with recent acute co

265 OUTCOMES trial compared the PCSK9 inhibitor alirocumab with placebo, each added to high-intensity or

266 e whether further cholesterol reduction with alirocumab would be cost-effective in patients with a re

267 The price of alirocumab would have to be reduced considerably to be c

268 The price of alirocumab would have to decrease from its original cost